It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We asked ...
Amgen (NASDAQ:AMGN – Free Report) had its price objective raised by Bank of America from $275.00 to $294.00 in a report released on Wednesday morning,Benzinga reports. Bank of America currently has an ...
On March 3, 2025, the FDA approved Celltrion’s denosumab biosimilars, STOBOCLO® (denosumab-bmwo; 60 mg/mL injection) and OSENVELT® (denosumab-bmwo; ...
Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...
Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents ...
The company's cash payout ratio is about 47%, giving it plenty of room to grow its dividend. Here's the bottom line: Amgen is ...
Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...
The prevalence of chronic sinusitis in China is about 8 percent, meaning it affects approximately 107 million people, ...
Amgen's new research and development facility in San Francisco. (courtesy photo) Amgen shares saw a slight uptick on March 5 as the company shared the news that it has started two critical late-stage ...
Jones Financial Companies Lllp increased its holdings in Amgen by 19.2% in Q4, acquiring 3,593 additional shares. Other ...
Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...
Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, the FDA cleared for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback